BCAAs in Concussion 3.0
Purpose
This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.
Conditions
- Concussion (Diagnosis)
- MTBI - Mild Traumatic Brain Injury
- Concussion, Brain
- Concussion
Eligibility
- Eligible Ages
- Between 11 Years and 23 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Males and females,11 - 23 years of age. 2. Weigh at least 40kg. 3. Meeting concussion criteria for the American Congress of Rehabilitative Medicine. a. One or more clinical signs or two or more acute symptoms with at least one VVE abnormality. 4. Present within 4 days of injury. 5. Post-menarchal females must have a negative urine pregnancy test. 6. Informed consent by the participant, or for participants <18 years old both informed consent by a parent/guardian and child assent.
Exclusion Criteria
- Evidence of moderate or severe TBI, including GCS <13, TBI requiring hospital admission, or TBI requiring neurosurgical intervention. 2. Prior concussion or TBI within 90 days. 3. Known history of maple syrup urine disease or known family history of maple syrup urine disease. 4. Any investigational drug use within 30 days prior to enrollment. 5. Participants who are pregnant, planning on becoming pregnant during the study duration, or breastfeeding. 6. Non-English speaking participants or parent/guardian.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Drug: Branched Chain Amino Acids |
The three BCAAs will be combined together into a powder formulation. |
|
|
Placebo Comparator Placebo |
The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation. |
|
Recruiting Locations
Havertown, Pennsylvania 19083
More Details
- Status
- Recruiting
- Sponsor
- Akiva Cohen
Detailed Description
Annually, approximately 2 million concussions occur in the pediatric and young adult population. Approximately 30% of those diagnosed with concussion will experience persisting symptoms lasting beyond 28 days. Concussion is a heterogeneous injury to the brain that precipitates a complex pathophysiological process that can result in a cascade of deleterious side effects. At present, there are no targeted therapeutics that can mitigate or prevent the deleterious effects of concussion. In preclinical, analysis of ipsilateral hippocampi isolated from mice after traumatic brain injury (TBI) demonstrated that only the concentrations of the three branched chain amino acids (BCAAs) (valine, isoleucine, and leucine) were significantly reduced after injury. When these brain-injured animals received dietary supplementation with BCAAs, the concentrations of these amino acids were restored in the injured hippocampus and the injured animals demonstrated significant cognitive improvement to levels comparable to those obtained in non-injured control animals. The pilot study (NCT01860404) provides evidence of BCAAs in concussed adolescents and young adults providing a dose-response effect in reducing concussion symptoms and a return to baseline physical activity in those treated with higher total doses of BCAAs. This third trial was developed to inform clinical practice around BCAA treatment in concussion in a new formulation.